BML, Inc. (TYO:4694)

Market Cap	130.63B -4.9%
Revenue (ttm)	150.26B +4.9%
Net Income	7.75B +23.7%
EPS	203.45 +26.7%
Shares Out	37.48M
PE Ratio	17.13
Forward PE	17.34
Dividend	125.00 (3.60%)
Ex-Dividend Date	Sep 29, 2026

Volume	177,100
Open	3,440.00
Previous Close	3,470.00
Day's Range	3,420.00 - 3,485.00
52-Week Range	3,370.00 - 4,385.00
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About BML, Inc.

BML, Inc. provides contract clinical testing and related services in Japan. The company offers a range of laboratory testing, such as biochemical and hematologic examination; laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispe...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 1955
• Employees: 4,612
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4694

Financial Performance

In fiscal year 2026, BML, Inc.'s revenue was 150.26 billion, an increase of 4.94% compared to the previous year's 143.19 billion. Earnings were 7.75 billion, an increase of 23.71%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 6, 2026

Data Sources Report a data error